Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection

The BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech) is being utilised internationally for mass COVID-19 vaccination. Evidence of single-dose protection against symptomatic disease has encouraged some countries to opt for delayed booster doses of BNT162b2, but the effect of this strategy on rates of...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, Nick K, Rivett, Lucy, Seaman, Shaun, Samworth, Richard J, Warne, Ben, Workman, Chris, Ferris, Mark, Wright, Jo, Quinnell, Natalie, Shaw, Ashley, Goodfellow, Ian G, Lehner, Paul J, Howes, Rob, Wright, Giles, Matheson, Nicholas J, Weekes, Michael P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2021
Materias:
Epidemiology and Global Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8064747/
https://www.ncbi.nlm.nih.gov/pubmed/33830018
http://dx.doi.org/10.7554/eLife.68808

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8064747/
https://www.ncbi.nlm.nih.gov/pubmed/33830018
http://dx.doi.org/10.7554/eLife.68808

Ejemplares similares